Sociedad Americana de Hirudoterapia

Hirudin reduces nephropathy microangiopathy in STZ-induced diabetes rats by inhibiting endothelial cell migration

Mechanism study published in Life Sciences (2020)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Preclinical (animal)Genómica y proteómicaFarmacología salivalPang X et al. · Life sciences, 2020

Abstract

OBJECTIVE: Kidney is the most common location of microangiopathy in diabetic patients, and we designed this study to investigate the effects of hirudin on renal microangiopathy in STZ-induced diabetes rats and in vitro. METHODS: We established a diabetes model by intraperitoneal injection of STZ and administered hirudin daily by subcutaneous injection. HE staining was used to assess kidney pathological changes. Western blot and immunochemistry was used to detect the protein expression. Glomerular endothelial cells (GEC) in normal rats were assessed by cell scratch test for migration ability and tubule formation experiment for angiogenesis ability. RESULTS: Compared with DN rats without any treatment, the serum creatinine, serum Cys C, 24-hour urine protein of DN rats with hirudin treatment were significantly decrease, the kidney/body weight and glomerular area of DN rats with hirudin treatment were all significantly decrease, and also significant improvement in renal pathology revealed by HE staining in DN rats after treating with hirudin. Moreover, we also found that hirudin coun not only significantly increase the prothrombin time and aivated partial thromboplastin time in DN rats, but also significantly decrease the expression of VEGF and TM-1 protein in kidney tissues of DN rats. In vitro, we found that high glucose could promote the migration and angiogensis of GEC, and significantly increased the expression of VEGF and Ang protein, but significantly decreased the expression of THBS1 and Arg1 protein. More importantly was that hirudin could inhibit the migration and angiogensis of GEC, and reversed HG-induced the expression of VEGF, Ang, THBS1 and Arg1 protein in GEC. In addition, we also found that hirudin could not only decrease HG-enhanced the activity of RhoA in GEC, but also decrease HG-enhanced the expression of p-MYPT1/MYPT1, p-p38/p38 protein in GEC. CONCLUSION: Hirudin reduces nephropathy microangiopathy in STZ-induced diabetes, and might be related to hirudin inhibiting glomerular endothelial cell migration and angiogenesis through Rho-kinase and subsequent p38MAPK/NF-kB signaling pathway.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAnimalsCell MovementDiabetes Mellitus, ExperimentalDiabetic AngiopathiesDiabetic NephropathiesEndothelial CellsFemaleGlucoseHirudinsKidney GlomerulusMaleNF-kappa B

Resumen

Hirudin reduces nephropathy microangiopathy in STZ-diabetic rats via inhibition of endothelial cell migration and abnormal angiogenesis — vascular renoprotection mechanism.

Por qué esto importa para la hirudoterapia

This study investigated hirudin's effects on renal microangiopathy in STZ-induced diabetic rats and in glomerular endothelial cells (GEC) in vitro, finding that hirudin decreased serum creatinine, Cys C, 24-hour urine protein, kidney/body weight, and glomerular area, and improved renal pathology on HE staining. Hirudin prolonged prothrombin and activated partial thromboplastin times, decreased VEGF and TM-1 protein expression in kidney tissue, inhibited GEC migration and angiogenesis under high-glucose conditions, and modulated RhoA, p-MYPT1/MYPT1, and p-p38/p38 signaling. This work is relevant to ASH's domain as it examines hirudin's effects on microvascular pathology in diabetic nephropathy, including its influence on clotting parameters. However, the study was conducted entirely in an STZ-induced diabetic rat model and in vitro cell experiments, with no human or clinical data presented.

Citación

Hirudin reduces nephropathy microangiopathy in STZ-induced diabetes rats by inhibiting endothelial cell migration.

Pang X et al. · Life sciences, 2020

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.